Kymriah Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in immuno-oncology research, regulatory approvals for cell therapies, increased clinical success in refractory cancers, expansion of specialized treatment centers, rising investment in cell therapy infrastructure.

The growth in the forecast period can be attributed to growing pipeline of car-t indications, increasing adoption in adult patient populations, expansion of manufacturing automation, rising focus on cost optimization in cell therapies, broader reimbursement coverage. Major trends in the forecast period include increasing adoption of car-t cell therapies, expansion of personalized cancer treatment approaches, growing focus on advanced cell processing techniques, rising integration of data-driven patient monitoring, enhanced manufacturing scalability for cell therapies.

The rising prevalence of hematological cancer is expected to propel the growth of the kymriah market going forward. Hematological cancer includes cancers that impact the blood, bone marrow, lymph nodes, and lymphatic system. The rise in hematological cancer can be attributed to several factors, including an aging population, genetic factors, immune system disorders, and lifestyle factors. Kymriah is used in hematological cancers to treat certain types of leukemia and lymphoma by utilizing CAR-T cell therapy to target and destroy cancerous cells. For instance, in September 2024, according to the Leukemia & Lymphoma Society (LLS), a US-based charitable organization dedicated to fighting blood cancer worldwide, in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every 3 minutes. In 2024, it is estimated that 187,740 people will be diagnosed with these hematological cancers. Therefore, the rising prevalence of hematological cancer is driving the growth of the kymriah market.

The growing demand for personalized therapies is significantly driving the growth of the kymriah market in the future. Personalized therapies are customized medical treatments designed to suit an individual's specific genetic, environmental, and lifestyle characteristics, aiming to enhance effectiveness and reduce adverse effects. The demand for personalized therapies is attributed to factors such as advancements in genetic research, a better understanding of diseases at the molecular level, and improved diagnostic tools. Kymriah is beneficial for personalized therapies as it is a gene therapy tailored to treat certain types of cancer by using the patient's immune cells to target and attack cancer cells. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. Therefore, the growing demand for personalized therapies is fueling the growth of the kymriah market.

The key trend in the Kymriah market is the focus on enhancing treatment accessibility and optimizing the safety management of CAR-T cell therapies to support broader real-world adoption. CAR-T therapies involve engineering a patient’s own T cells to recognize and eliminate malignant cells, offering a highly targeted approach for certain leukemias and lymphomas. For instance, in June 2024, Novartis AG, a Switzerland-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for significant updates to the Kymriah (tisagenlecleucel) prescribing information, including the removal of the Risk Evaluation and Mitigation Strategy (REMS) program requirements. This regulatory decision reflects the FDA’s determination that existing safety data, clinical experience, and updated labeling are sufficient for managing known risks without additional REMS controls. By simplifying access and reducing institutional burdens related to certification and training, the updated Kymriah framework supports wider patient availability while maintaining essential safety standards. The move underscores ongoing efforts to expand the reach of CAR-T therapies and streamline their integration into routine clinical practice.

Major companies operating in the kymriah market are Novartis AG.

North America was the largest region in the kymriah market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kymriah market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the kymriah market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the kymriah market by increasing costs associated with imported bioprocessing equipment, viral vectors, cell culture media, and cryopreservation materials used in CAR-T manufacturing. North America and Europe are most affected due to reliance on cross-border sourcing of advanced biologics inputs, while Asia-Pacific faces higher costs for facility setup and technology transfer. These tariffs are contributing to higher therapy production costs and extended manufacturing timelines. However, they are also encouraging localized manufacturing, regional supply chain development, and investments in domestic cell therapy production capabilities.

The kymriah market research report is one of a series of new reports that provides kymriah market statistics, including kymriah industry global market size, regional shares, competitors with a kymriah market share, detailed kymriah market segments, market trends and opportunities, and any further data you may need to thrive in the kymriah industry. This kymriah market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Kymriah is a CAR-T cell therapy that modifies a patient's T cells to target and attack cancer cells. It is used to treat specific blood cancers by extracting, modifying, and reinfusing T cells to recognize cancer markers. This innovative treatment has proven highly effective in patients with cancers resistant to other therapies, offering a potentially life-saving option.

The main types of kymriah formulations are injectable formulations (intravenous) and customized patient-specific formulations. An injectable intravenous formulation delivers medication directly into a vein for precise, rapid, and controlled treatment, often used in various disorders. It is applicable in various indications, such as the treatment of B-cell acute lymphoblastic leukemia, treatment of diffuse large B-cell lymphoma, treatment of follicular lymphoma, and others for several patient demographics, including pediatric patients, adult patients, and geriatric patients. It is distributed through various distribution channels, such as direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, and used by several end users, including hospitals, oncology clinics, hematology treatment centers, and research institutions.

The kymriah market consists of sales of leukapheresis kits, infusion kits, and bioreactors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.